Unicycive Therapeutics (NASDAQ:UNCY – Get Free Report) and Phathom Pharmaceuticals (NASDAQ:PHAT – Get Free Report) are both small-cap healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their dividends, earnings, analyst recommendations, institutional ownership, valuation, risk and profitability.
Valuation & Earnings
This table compares Unicycive Therapeutics and Phathom Pharmaceuticals”s top-line revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Unicycive Therapeutics | $680,000.00 | 214.44 | -$26.56 million | ($1.75) | -2.99 |
| Phathom Pharmaceuticals | $175.11 million | 4.01 | -$221.25 million | ($1.28) | -6.78 |
Insider & Institutional Ownership
40.4% of Unicycive Therapeutics shares are held by institutional investors. Comparatively, 99.0% of Phathom Pharmaceuticals shares are held by institutional investors. 6.0% of Unicycive Therapeutics shares are held by company insiders. Comparatively, 9.3% of Phathom Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
Profitability
This table compares Unicycive Therapeutics and Phathom Pharmaceuticals’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Unicycive Therapeutics | N/A | -91.50% | -61.47% |
| Phathom Pharmaceuticals | -41.34% | N/A | -20.81% |
Volatility and Risk
Unicycive Therapeutics has a beta of 1.79, suggesting that its share price is 79% more volatile than the S&P 500. Comparatively, Phathom Pharmaceuticals has a beta of 0.51, suggesting that its share price is 49% less volatile than the S&P 500.
Analyst Ratings
This is a breakdown of recent ratings and target prices for Unicycive Therapeutics and Phathom Pharmaceuticals, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Unicycive Therapeutics | 1 | 1 | 5 | 0 | 2.57 |
| Phathom Pharmaceuticals | 1 | 1 | 6 | 1 | 2.78 |
Unicycive Therapeutics currently has a consensus price target of $18.75, indicating a potential upside of 258.10%. Phathom Pharmaceuticals has a consensus price target of $21.25, indicating a potential upside of 144.84%. Given Unicycive Therapeutics’ higher possible upside, analysts clearly believe Unicycive Therapeutics is more favorable than Phathom Pharmaceuticals.
Summary
Phathom Pharmaceuticals beats Unicycive Therapeutics on 9 of the 15 factors compared between the two stocks.
About Unicycive Therapeutics
Unicycive Therapeutics, Inc., a biotechnology company, engages in developing novel therapies for kidney diseases in the United States. It is developing Renazorb for treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis; and UNI 494, which is in Phase 1 clinical trials for treatment of acute kidney injury. The company was incorporated in 2016 and is based in Los Altos, California.
About Phathom Pharmaceuticals
Phathom Pharmaceuticals, Inc., biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada for an investigational potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach. It is also developing vonoprazan for the treatment of erosive gastroesophageal reflux disease; and in combination with antibiotics for the treatment of Helicobacter pylori infection. The company was incorporated in 2018 and is headquartered in Florham Park, New Jersey.
Receive News & Ratings for Unicycive Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Unicycive Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
